GB2531093A — Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
Assigned to GW Pharma Ltd · Expires 2016-04-13 · 10y expired
What this patent protects
Cannabidiol (CBD) for use in the treatment of epilepsy where the epilepsy is a treatment-resistant epilepsy (TRE) and where the CBD is present in an amount that reduces total convulsive seizure frequency by greater than 50% with respect to seizure frequency achieved on concomitan…
USPTO Abstract
Cannabidiol (CBD) for use in the treatment of epilepsy where the epilepsy is a treatment-resistant epilepsy (TRE) and where the CBD is present in an amount that reduces total convulsive seizure frequency by greater than 50% with respect to seizure frequency achieved on concomitant anti-epileptic drugs (AED). The TRE may especially be Dravet syndrome, myoclonic absence seizures, or febrile infection related epilepsy syndrome (FIRES). CBD may be administered in combination with two or more concomitant AEDs, especially clobazam, levetiracetam, topiramate, stiripentol, phenobarbital, lacsamide, valproic acid, zonisamide, perampanel, and fosphenytoin. An especially preferred AED is clobazam (Onfi). Preferably the dose of CBD is from 5 mg/kg/day to 25 mg/kg/day.
Drugs covered by this patent
- Epidiolex (CANNABIDIOL) · Jazz Pharms Res
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.